Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases from AprilBio
· APB-A1 targets the clinically validated CD40L/CD40 biology which is central to a wide range of attractive neuroimmune indications · APB-A1 is a novel and differentiated biotherapeutic with strong preclinical evidence · Deal accelerates the Lundbeck strategy to expand R&D activities within neuroimmunology · Follows the Lundbeck strategy of tractable and biomarker driven development programs in diseases of high unmet needH. Lundbeck A/S (Lundbeck) announced that it has entered into a definitive agreement with AprilBio Co., Ltd. (AprilBio), a biopharmaceutical company based in